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Medications are frequently used for the treatment of patients with the irritable bowel syn-
drome (IBS), although their actual benefit is often debated. In fact, the recent progress in
our understanding of the pathophysiology of IBS, accompanied by a large number of preclin-
ical and clinical studies of new drugs, has not been matched by a significant improvement
of the armamentarium of medications available to treat IBS. The aim of this review is to
outline the current challenges in drug development for IBS, taking advantage of what we
have learnt through the Rome process (Rome I, Rome II, and Rome III). The key questions
that will be addressed are: (a) do we still believe in the “magic bullet,” i.e., a very selective
drug displaying a single receptor mechanism capable of controlling IBS symptoms? (b) IBS
is a “functional disorder” where complex neuroimmune and brain-gut interactions occur
and minimal inflammation is often documented: do we need to target gut motility, vis-
ceral sensitivity, or minimal inflammation? (c) are there validated biomarkers (accepted by
regulatory agencies) for studies of sensation and motility with experimental medications
in humans? (d) do animal models have predictive and translational value? (e) in the era
of personalized medicine, does pharmacogenomics applied to these medications already
play a role? Finally, this review will briefly outline medications currently used or in devel-
opment for IBS. It is anticipated that a more focused interaction between basic science
investigators, pharmacologists, and clinicians will lead to better treatment of IBS.
Keywords: drug targets, translational medical research, brain-gut interactions, drug selectivity, biomarkers,
5-hydroxytryptamine, transient receptor potential channels, neuroimmune intestinal interactions
INTRODUCTION
Irritable bowel syndrome (IBS) is a common functional gastroin-
testinal disorder, characterized by recurrent abdominal pain or
discomfort in combination with disturbed bowel habits in the
absence of identifiable organic cause. Many medications are used
for the treatment of patients with IBS, although their actual benefit
is often a matter of debate. In particular, only a few are specif-
ically labeled for IBS. In fact, notwithstanding great progress in
our understanding of the pathophysiology of IBS thanks to a large
number of preclinical and clinical studies of new drugs, the specific
armamentarium of medications available is scant. The aim of this
review is to outline the current challenges in drug development for
IBS, taking advantage of what we have learned through the Rome
process (from Rome I in the 1980s to Rome III published in 2006;
Drossman, 2006).
The key questions that will be addressed are: (a) do we still
believe in the “magic bullet,” i.e., a very selective drug displaying a
single receptor mechanism capable of controlling IBS symptoms?
(b) IBS is a “functional disorder” where complex neuroimmune
and brain-gut interactions occur and minimal inflammation is
often documented: do we need to target gut motility, visceral
Abbreviations: EMA, European Medicines Agency; ENS, enteric nervous system;
FDA, food and drug administration; 5-HT, 5-hydroxytryptamine; IBS, irritable
bowel syndrome.
sensitivity, or minimal inflammation? (c) are there validated bio-
markers (accepted by regulatory agencies) for studies of sensation
and motility with experimental medications in humans? (d) do
animal models have predictive and translational value? (e) in the
era of personalized medicine, does pharmacogenomics applied
to these medications already play a role? Finally, this review will
briefly outline medications currently used or in development for
IBS. It is anticipated that a more focused interaction between basic
science investigators, pharmacologists, and clinicians will lead to
better treatment of IBS.
THE “MAGIC BULLET”: A CONCEPT THAT NEEDS
RETHINKING
The key pharmacodynamics, pharmacokinetic, and safety features
for drugs to be used in the treatment of IBS are outlined in Table 1.
A selective drug is defined as a compound interacting only with
one receptor subtype and leaving other receptors unaffected at
concentrations achieved at therapeutic doses. The literature on
the treatment of IBS has often resorted to the concept of the
“magic bullet,” i.e., a very selective drug displaying a single recep-
tor mechanism capable of controlling IBS symptoms (Camilleri
et al., 2006a). This was often considered the key to efficacy avoid-
ing side-effects. This approach is no longer ideal because of several
important pitfalls.
First, drug selectivity is always a relative concept, which ignores
the basic fact that most molecules, even at therapeutic doses,
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Table 1 | Key features for drugs to be used in the treatment of IBS.
Key features
Pharmacodynamics The drug should target a whole pathophysiological
mechanism rather than a single receptor
Possible targets: motility, secretion, visceral
sensitivity, neuroimmune interactions/minimal
inflammation, brain-gut axis
The effect should be maintained over time during
treatment
Pharmacokinetics Good oral bioavailability (unless local action in the gut
is specifically wanted)
Half-life allows once daily dosing
No metabolites with different or unwanted
pharmacological actions
Avoid CYP substrates with high likelihood of drug
interactions
Consider interactions with food or herbal products
Safety Specificity cannot always avoid off-target effects
because the same receptor/system also mediates
other effects
A drug can also hit antitargets (i.e., unwanted targets),
another source of side-effects
may have several, sometimes disparate biological effects (i.e., hit
a large number of targets in the pharmacological space; Garcia-
Serna et al., 2010; Kawasaki and Freire, 2011). These effects may
depend on the fact that a single receptor/effector pathway plays a
role in different systems, so that even selective compounds have
off-target effects (Table 1). In addition, there are many instances
when the compound is endowed with additional pharmacolog-
ical properties that hit the so-called antitargets (i.e., unwanted
targets), responsible for side-effects, which are clarified only after
the compound has undergone clinical trials. The classical example
is provided by the cardiac side-effects due to hERG K+ chan-
nel blockade by the early 5-HT4 receptor agonists (Tonini et al.,
1999).
The second issue is that the multifactorial pathophysiology
of IBS (with multiple brain-gut and neuroimmune interactions)
makes it unrealistic to expect that drugs acting on a single receptor
may achieve substantial therapeutic gain over placebo in an area
where the placebo response rate is substantial (approaching 40%
across all randomized controlled trials; Ford and Moayyedi, 2010).
As in other fields (Morphy et al., 2004), evidence suggests that a
balanced modulation of multiple targets can provide a superior
therapeutic effect and side effect profile compared to the action of
a selective ligand. Designed multiple ligands that hit a large vari-
ety of targets have been produced through rational approaches
in which structural features from selective ligands are combined
(Morphy et al., 2004). A key challenge in the design of multiple
ligands is attaining a balanced activity at each target of interest
with a suitable pharmacokinetic profile.
The third issue is that mechanisms underlying symptoms in
IBS may differ among patients, hence the need to consider using
multiple therapies. With selective drugs, primary clinical end-
points were achieved in less than 70% of patients with the approved
agents such as tegaserod or alosetron (Camilleri et al., 2000;
Muller-Lissner et al., 2001; Cremonini et al., 2003). On the other
hand, it seems reasonable to propose treatment with combination
therapy, which is the rule when treating medical conditions such as
hypertension or asthma,when monotherapy is no longer adequate.
Because of the redundancy of mechanisms controlling neurosen-
sory, neuromuscular, and neuroimmune functions in the gut, it
is conceivable that effective treatment of functional gut disorders
may require combination therapy.
One example is provided by tachykinin receptor antagonists,
which have so far given disappointing results because of inherent
differences among animal models and humans: it has been sug-
gested that the analgesic efficacy of multi- or pan-tachykinin recep-
tor antagonists is superior to that of mono-receptor antagonists
(Holzer, 2004a).
When drugs address a specific target (e.g., a symptom such as
visceral hypersensitivity or motility), heterogeneity in the patho-
physiology impacts negatively on the therapeutic gain, if patients
are not carefully selected in a clinical trial. Indeed, some of the
disappointing results of the past can be ascribed to the lack of
understanding of pathophysiology: the same symptom (e.g., diar-
rhea) does not necessarily depend on the same pathways in all
patients.
Thus, new drugs should target a pathophysiological mechanism
(provided that it is known!), rather than a specific receptor; on the
other hand, recruiting carefully selected patient subgroups may
significantly reduce the generalizability of the results of the trial.
Pharmacokinetics may help to achieve gut selectivity and
reduce side-effects. This approach is particularly relevant when
there are potential actions outside the gut, as it is indeed the case
with peripherally restricted opioid receptor antagonists (such as
methylnaltrexone and alvimopan), which do not cross the blood
brain barrier and, in addition, have very low oral bioavailabil-
ity (De Ponti, 2002; Holzer, 2004b). An example of minimally
absorbed compound is also the guanylate cyclase-C agonist lina-
clotide (Wensel and Luthin, 2011; Busby et al., 2013), which is now
FDA- and European Medicines Agency (EMA)-approved for IBS
with constipation.
Another important pharmacokinetic property is the lack of
interactions with food or other drugs. Significant interactions with
CYP2D6 and CYP3A4 should be predicted in early drug discovery
because of their involvement in drug metabolism with important
pharmacogenetic aspects.
Finally, as regards safety aspects, apart from the standard safety
evaluations, two issues deserve special attention following the
experience with cisapride (torsades de pointes associated with
QT prolongation; De Ponti et al., 2001) and alosetron (ischemic
colitis; Moynihan, 2002). It is clear that even very rare events
may negatively impact the risk/benefit balance of drugs that are
used to provide symptom improvement of non-serious (though
troublesome) diseases such as IBS (De Ponti et al., 2002; Tack
et al., 2012). It is remarkable that in IBS with diarrhea, Shah
et al. (2012) found that one adverse event resulting in study
Frontiers in Pharmacology | Gastrointestinal Pharmacology February 2013 | Volume 4 | Article 7 | 2
De Ponti New drugs for IBS
discontinuation occurred for every 2.3 and 2.6 patients who ben-
efited, respectively, from tricyclic antidepressants and alosetron,
i.e., the number needed to harm was approximately 3. This is
quite low, considering the numbers needed to treat reported in
the literature for drugs in IBS (Brandt et al., 2009; Camilleri and
Mayer, 2009; Menees et al., 2012). Shah et al. (2012) conclude
that, rather than simply focusing on the number needed to treat,
clinicians should be aware of harm when using pharmacotherapy
for IBS.
IBS AS A “FUNCTIONAL DISORDER”: NEW PERSPECTIVES
AND GLOBAL REGULATORY FRAMEWORK
The classical concept of IBS as a functional disorder derives from
the fact that no organic cause can be identified and the diagnosis of
IBS is one of exclusion after other disorders have been ruled out. In
addition, the precise mechanisms underlying symptom generation
are unknown.
However, research of the past 20 years has provided signifi-
cant advances in the understanding of the pathophysiology of
IBS, with an emerging consensus that the various clinical man-
ifestations (including non-gastrointestinal comorbid symptoms)
of chronic abdominal pain can best be viewed as a dysregula-
tion in the complex interplay between events occurring in the
gut lumen (including microbiota), the mucosa, the enteric ner-
vous system (ENS), and the central nervous system (Mayer and
Tillisch, 2011; Matricon et al., 2012). This dysregulaton leads to
alterations in sensation, motility, brain-gut interactions, and neu-
roimmune interactions. Considerable evidence documents that
sensitizing proinflammatory mediators, mast cells and their prod-
ucts, tryptases, are increased in tissues of patients with colorectal
hypersensitivity (Cenac et al., 2007; Balestra et al., 2012; Buhner
et al., 2012).
It has been shown that colonic mast cell infiltration and media-
tor release in proximity to mucosal innervation may contribute
to abdominal pain perception in IBS patients (Barbara et al.,
2004). Indeed, mucosal mast cell mediators from IBS patients
excite rat nociceptive visceral sensory nerves (Barbara et al., 2007).
In a recent study (Balestra et al., 2012), mucosal biopsies were
obtained from the descending colon of patients with IBS and
controls. Mucosal mast cells were identified immunohistochemi-
cally. The impact of spontaneously released mucosal mediators on
guinea pig electrically stimulated longitudinal muscle myenteric
plexus (LMMP) preparations was assessed in vitro by means of
selective receptor antagonists and inhibitors. Patients with IBS
showed an increased mast cell count compared with controls.
Application of mucosal mediators of IBS to LMMPs potentiated
cholinergic twitch contractions, an effect directly correlated with
mast cell counts and mediated by activation of prostanoid recep-
tors, TRPV1, and P2X receptors. These results support the role
of mucosal inflammatory mediators and mast cell activation in
altered motor function of IBS.
It is also intriguing that, in patients with IBS, 5-HT spontaneous
release was significantly increased irrespective of bowel habit and
correlated with mast cell counts and the severity of abdominal
pain. This suggests that increased 5-HT release contributes to
development of abdominal pain in IBS, probably through mucosal
immune activation (Cremon et al., 2011).
Several studies have reported the onset of IBS-like symptoms
following established bacterial or viral infections of the GI tract
(Barbara et al., 2009). This so-called “postinfectious” IBS occurs in
approximately 10% of patients undergoing a documented infec-
tious gastroenteritis, and risk factors to develop symptom per-
sistence are longer duration of the gastroenteritis, female sex,
psychosocial stressors at the time of the infection, and psycho-
logical factors such as anxiety or depression. Although a causal
relationship between abdominal pain and acute or chronic infec-
tions cannot be established most of the times, it is tempting to
speculate that host-microbial interactions in vulnerable individu-
als during the early phase of the disorder may lead to permanently
altered immune response, which then continues to play a role when
symptoms persist in the absence of the infectious organism.
The participation of the gut microenvironment in the patho-
physiology of IBS is suggested by studies indicating an interplay
between luminal factors including the microbiome, the epithe-
lial barrier, and the mucosal immune system (Stanghellini et al.,
2010; Camilleri et al., 2012). In an animal model (McVey Neufeld
et al., 2013), microbiota were shown to be necessary for normal
excitability of gut sensory neurons and this provides a potential
mechanism for the transfer of information between the microbiota
and the nervous system.
In postinfectious IBS and in IBS with diarrhea, decreased
expression and structural rearrangement of tight junction pro-
teins in the small bowel and colon may lead to increased intestinal
permeability. These abnormalities might contribute to the outflow
of antigens through the epithelium, causing overstimulation of the
mucosal immune system. Accordingly, subgroups of patients with
IBS show higher numbers and activation of mucosal immuno-
cytes, especially mast cells. Immune factors, released by these cells,
including proteases, histamine, and prostanoids, might also partic-
ipate in maintaining the permeability dysfunction and contribute
to the activation of abnormal neural responses, which, in turn,
are involved in abdominal pain perception and changes in bowel
habits.
All these mechanisms represent new therapeutic targets in IBS.
Here, it is important to remember that probiotics are also currently
viewed as an attractive therapeutic option in IBS because of their
recognized safety and of their documented biological effects on the
host. Preclinical studies have shown that some probiotic strains
exhibit potentially useful properties including anti-inflammatory
effects, improvement of mucosal barrier homeostasis, beneficial
effects on intestinal microbiota, and a reduction of visceral hyper-
sensitivity. However, it remains to be determined to what extent
a beneficial effect on these parameter translates to a significant
effect on clinical outcomes: although the effect of probiotics on
IBS is positive in some randomized, controlled studies, the gain
over placebo is small and identification of a tailored probiotic
approach for subgroups of patients represents a future challenge.
The complex neuroimmune and brain-gut interactions some-
times associated with minimal mucosal inflammation (Ford and
Talley, 2011) and neuroplastic changes in the ENS (Giaroni et al.,
1999) pose several questions as regards potential targets for phar-
macological intervention: should the therapeutic focus be pri-
marily gut motility, visceral sensitivity, or minimal inflammation?
Assessment of these parameters in humans can be undertaken by
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using a variety of invasive and non-invasive techniques, some well
established and others requiring further validation. By using these
techniques, alterations in both sensory and motor function have
been reported in IBS and our understanding of sensorimotor dys-
function has indeed increased. Thus, inflammatory, immunologic,
and other processes, as well as psychosocial factors such as stress,
can alter the normal patterns of sensitivity and motility through
alterations in local reflex activity or via altered neural processing
along the brain-gut axis. A firm relationship between sensorimo-
tor dysfunction and the production of symptoms, however, has
been difficult to show. Thus, the clinical relevance of the former
requires further research.
In this context, it is important to remember that in 2003 the
EMA adopted a document produced by the Efficacy Working Party
on the “Points to consider on the evaluation of medicinal products
for the treatment of the irritable bowel syndrome” (EMA, 2003).
Although the document now needs to be updated (it still refers
to Rome II criteria), a key statement is that “The patient’s global
assessment of symptoms and abdominal discomfort/pain should be
used as the two primary endpoints. Statistically significant changes
must be found in both parameters.” Thus, clinical efficacy must
rely on clinical endpoints in the patient’s perspective, for instance
through the global assessment of multiple symptoms. Mecha-
nistic (pathophysiological) studies provide a rationale for drug
development, but do not generally predict symptomatic success
and do not necessarily identify the most appropriate dose for
clinical trials. An important goal is to develop non-invasive tests
that identify important pathophysiological mechanisms and assess
symptom pattern in short-term (4 weeks) therapeutic trials that
pave the way to longer trials. Notably, the EMA document care-
fully considers the duration of efficacy trials, stating that they
must be long enough to determine whether the response is sus-
tained and to determine the effects of treatment withdrawal. A
duration of 6 months of active treatment is considered neces-
sary considering the cyclic and non-life threatening nature of the
disease.
For inclusion and exclusion criteria for IBS, the current EMA
“Points to consider” document refers to Rome II criteria (current
Rome III criteria differ from Rome II and, notably, the Rome IV
process is expected to start in 2013). A revised EMA guideline is
awaited soon and should come into force by the end of 2013. A
key issue that needs to be addressed, apart from the update to
Rome III, is the discrepancy with the FDA guidance issued in 2012
(FDA, 2012). Indeed, the EMA document recommends the two
co-primary endpoints indicated above, whereas the FDA guid-
ance recommends a primary endpoint that measures the effect of
treatment on two major IBS signs and symptoms: abdominal pain
and abnormal defecation (stool frequency or stool consistency,
depending on subtype of IBS). The FDA guidance also acknowl-
edges that patient-reported outcome (PRO) measures of the signs
and symptoms of the condition are the only currently available
measures that can adequately define a treatment effect in a clinical
trial. In addition, because of the limitations of using a single-item
patient-reported rating of overall change as a primary endpoint,
the FDA document recommends the development of a multi-item
PRO instrument. The PRO measure(s) should capture all the clin-
ically important signs and symptoms of the target population. The
ongoing regulatory discussion will certainly help all those involved
in clinical trials to plan future research.
Linaclotide may serve as an example of the current regulatory
situation, with differences in endpoints recommended by the FDA
and the EMA: the efficacy and safety of this agent in patients with
IBS-C was evaluated in two randomized, placebo-controlled Phase
3 trials. These trials were designed according to both FDA and
EMA guidelines and findings based on FDA-recommended end-
points were reported in two recent studies (Chey et al., 2012; Rao
et al., 2012), whereas the findings of a planned, separate analysis
of both trials based on the distinct efficacy parameters prespeci-
fied for EMA submission were published separately (Quigley et al.,
2013).
In closing this section, it should be remembered that, over the
past 25 years, the Rome process has insisted on clinical features to
diagnose IBS on the assumption that grouping of patients with
similar features facilitates identification of patients most likely to
respond to a given pharmacological agent, but this is not nec-
essarily so because the same symptom (pain) may have several
underlying pathophysiological mechanisms. This explains the crit-
icism raised by some investigators against the Rome criteria (Dang
et al., 2012). On the other hand, it must be acknowledged that
there are several reasons to establish an accurate diagnosis of IBS:
to relieve patient uncertainty and initiate the most appropriate
treatment, avoiding the burden of unnecessary medications or
diagnostic procedures and surgeries (Mearin and Lacy, 2012). In
other words, the Rome criteria try to transform the diagnosis of
IBS from one of exclusion into a positive diagnosis based on his-
tory, physical examination, use of precise diagnostic criteria in the
absence of specific alarm features.
BIOMARKERS FOR IBS
Biomarkers are objectively measurable indicators of normal or
pathological processes or pharmacological responses to a ther-
apeutic intervention (Anonymous, 2001). In order to improve
development and usage of biomarkers, a score system of differ-
ent types of biomarkers has been proposed, depending on their
impact on drug development (Wehling, 2009).
Positive modifications of biomarkers which imply improve-
ment of the disease can be taken as endpoints during drug devel-
opment. To provide a more complete picture, a therapeutic target
can coincide with the biomarker (e.g., TNFα) or, as a component
of the disease mechanism, modulate it (e.g., NF-κB).
Unfortunately, as stated in the 2012 FDA document, no vali-
dated and accepted biomarker exists in IBS. In addition, the limited
repertoire of clinical manifestations of sensorimotor disorders of
the gut such as IBS can actually derive from multiple mechanisms,
leading in turn to similar symptoms. In many clinical programs of
new drugs for IBS, the emphasis was primarily on symptom assess-
ment of broad groups of patients identified by the Rome criteria.
As already discussed above, this approach was not ideal and it not
surprising that drugs of potential value have been abandoned.
Certain biomarkers can, in a limited fashion, be used to pre-
dict the success of a drug in IBS or to understand its mode of
action. These studies may be incorporated in the recommended
steps for drug development, but should be viewed only as prelim-
inary/complementary steps of the development program, which
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must comply with the regulatory guidance quoted in the previous
section.
Currently established tests that can be used as potential bio-
markers for clinically relevant endpoints in IBS include the
following.
INTRALUMINAL MEASUREMENTS OF COLONIC OR RECTAL MOTILITY
AND SENSATION
Intraluminal measurements may serve as biomarkers for motor
or sensory modulation in IBS. Manometry has long been used
for pathophysiological investigations (Camilleri et al., 2008) and
can be used as a useful technique to study the effects of drugs
on colonic motility (De Schryver et al., 2002; Dinning and Scott,
2011). Another possible test is intracolonic measurement of post-
prandial tone using a barostat, which, in healthy subjects (von der
Ohe et al., 1994), showed the potential of 5-HT3 receptor antag-
onists to prevent diarrhea and other postprandial symptoms in
diseases including IBS and carcinoid diarrhea (von der Ohe et al.,
1993). This indicates that measuring tone intraluminally may be a
useful biomarker for preliminary tests before subsequent trials for
efficacy. A recent study in healthy subjects (Sweetser et al., 2009)
investigated the effects of lubiprostone on colonic sensation and
motility with the following endpoints: colonic compliance, fasting
and postprandial tone and motility indexes, pain thresholds, and
sensory ratings to distensions. This investigation well exemplifies
the potential of pharmacodynamic studies in drug development.
Although testing visceral sensitivity may provide useful mech-
anistic insights when developing new medications, results always
require careful interpretation and are sometimes disappointing.
For instance, alosetron was shown to alter colonic compliance, but
not colonic sensitivity to isobaric distension (Delvaux et al., 1998).
Previously, the κ opioid receptor agonist fedotozine was shown to
decrease sensitivity to colonic distension, but the therapeutic gain
in placebo-controlled studies in IBS was found to be of insuffi-
cient magnitude for further development (Dapoigny et al., 1995;
Delvaux et al., 1999; Ness, 1999). Asimadoline is another exam-
ple of drug tested for its effect on visceral sensitivity in humans
(Delgado-Aros et al., 2003).
One disadvantage of sensation biomarkers is that the sample
size required to avoid a type 2 error while assessing clinically mean-
ingful effect sizes is higher than with transit endpoints in healthy
volunteers and probably even higher in patients. Nevertheless,
these sample sizes (12–20 per treatment arm) are still more prac-
tical than testing symptom endpoints, which require much larger
samples. Thus, a 25–30% effect size can be demonstrated with∼20
subjects per treatment arm in sensation-based studies and∼12 per
treatment arm in studies of transit, on the basis of the variability
reported in published studies (Camilleri et al., 2006b).
RADIOPAQUE MARKERS FOR COLONIC TRANSIT
The radiopaque marker test for colonic transit is a widely avail-
able test, as shown by early studies with loperamide for diarrhea
and fiber for constipation, where radiopaque markers were used
to assess whole gut transit time (Cann et al., 1984a,b). The over-
all effects of drugs for IBS can be predicted by the marker transit
test, although transit times are not characteristic of IBS (Horikawa
et al., 1999) and other studies addressing more specific endpoints
suggest that the colonic marker transit time (<15 or >60 h) accu-
rately predicts the extremes of stool consistency, with significant
overlap for transit times between those extremes (Degen et al.,
2001).
RADIOSCINTIGRAPHIC MARKERS FOR COLONIC TRANSIT
Scintigraphic transit measurements are sufficiently well charac-
terized to allow meaningful pharmacodynamic conclusions on
the effect of therapeutic agents (Cremonini et al., 2002; Camil-
leri, 2010a; Vazquez-Roque et al., 2012). Namely, several examples
support the use of detailed colonic transit measurement in the
development of medications for IBS-associated changes in bowel
function. First, alosetron (a 5-HT3 receptor antagonist) slows over-
all colonic transit and, on average, increases the time for emptying
the ascending colon by 50% (Viramontes et al., 2001a). Second,
tegaserod (a 5-HT4 receptor agonist) accelerates overall colonic
transit and, on average, halves the time for emptying the ascend-
ing colon (Prather et al., 2000), and several studies showed that
this medication was effective in the treatment of IBS with con-
stipation (Muller-Lissner et al., 2001; Novick et al., 2002; Kellow
et al., 2003). However, tegaserod was withdrawn by the manufac-
turer for safety issues in 2007 and was made available only under a
restricted access program (Al-Judaibi et al., 2010). Finally, a more
recent example of use of scintigraphy to assess transit includes
linaclotide (Andresen et al., 2007).
URINE SUGARS FOR IN VIVO GUT PERMEABILITY
Because of the possible role of disruption of intestinal mucosal
barrier function in the pathophysiology of IBS, recently a urine
sugar (lactulose and mannitol) excretion test was validated in
patients with IBS and diarrhea (Rao et al., 2011). Urine sugars
at 0–2 and 8–24 h reflect small bowel and colonic permeability,
respectively and are increased in patients with IBS and diarrhea vs.
controls. This method can be applied to study the effects of agents
directed at mucosal pathophysiology, such as mast cell stabilizers
or modulators of microbial flora.
ANIMAL MODELS: PREDICTIVITY ISSUES AND CURRENT
ROLE
Translational medicine defines conditions and prerequisites to
transfer more reliable results obtained from preclinical biomed-
ical research to clinical applications, thus improving patient care
through timely and efficient promotion of clinical innovation.
A disease model should mimic the clinical disease condition as
much as possible and allow the investigation of unclear pathophys-
iological mechanisms toward the development of new potential
therapeutic options. In spite of undeniable differences among
species, animal models still represent the major source of infor-
mation about biological system and provide an invaluable means
to study complex physiological and biochemical interactions.
The predictivity of the disease model itself will substantially
depend on the efforts toward optimization and scientific validation
of the model, both in terms of resemblance and transferability to
humans. Pharmacological targets and biomarkers must be repro-
duced and be susceptible to pharmacological modulation in the
animal model, to ensure that the model is predictive of a therapeu-
tic effect in humans. The real translational value of a biomarker is
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represented by its capacity of being thoroughly informative after
its validation in clinical studies which provide the bedside to bench
approach.
An animal model used as a screening tool in drug development
should ideally reproduce different biomarkers providing multi-
ple endpoints to fully assess the spectrum of activity of a test
compound. Accurate selection of endpoints plays a pivotal role to
assure the translational value of disease models and should take
into account the sensitivity and specificity of each endpoint toward
prediction of activity.
Although development of new drugs for treatment of IBS can
be facilitated by preclinical animal models (Bulmer and Grundy,
2011; Holschneider et al., 2011), it must be acknowledged that a
single sufficiently predictive model of efficacy still does not exist
and investigators have the option to use multiple models to assess
different aspects of the pathophysiology of IBS. This section is
only intended as a brief outline of the most commonly used ani-
mal models of visceral pain and disturbed gastrointestinal motility,
which are reviewed elsewhere (Camilleri et al., 2006a).
MOTILITY
The techniques used to record motility or measure transit in ani-
mals may differ from techniques used in humans but the endpoints
are identical to those mentioned in the previous section.
VISCERAL PAIN
There are several forms of stimulation and endpoints to measure
visceral pain: (a) mechanical stimuli: experiments can be per-
formed in awake or anesthetized rats, and the most frequently
used stimulus of pain in animals is distension of a gut segment
with a balloon connected to a barostat to measure simultaneously
compliance and the response to the painful stimulus (Rouzade
et al., 1998). Poor standardization of methods across laboratories
is a drawback of these investigations. (b) Chemical stimuli: infus-
ing glycerol into the rat colon through a chronically implanted
catheter induces abdominal cramps. This model is considered rel-
evant because intracolonic glycerol induces abdominal pain in
humans and mimics pain reported by patients with IBS (Louvel
et al., 1996). (c) Other stimuli: the significance of other models of
visceral pain, such as the“writhing test”(consisting of an intraperi-
toneal injection of an irritant compound such as acetic acid), is
questionable.
In the aforementioned models, it is important to distinguish
between evaluation of allodynia (decrease in the threshold of
sensitivity to distension) and hyperalgesia (enhanced response to
painful stimulus). A commonly used endpoint is the contraction
of abdominal muscles induced by rectal or colorectal distension in
the rat; the contractions are recorded by electromyography, where
the number of spike bursts correlates with the intensity of the
stimulus applied (Morteau et al., 1994).
Visceral distension also induces viscero-visceral reflexes, such as
relaxation of anal sphincters during rectal distension or change in
blood pressure, which is a pseudoaffective response used to assess
visceral pain.
In summary, selection of one or more definitive animal models
of visceral hyperalgesia is not possible and using results from more
than one animal model may enhance the probability of selecting
effective drugs for further development. Since pain, though a
major problem, is not the only symptom affecting quality of life,
animal models detailing the effects of drugs on motility and vis-
ceral sensitivity may add a further dimension to the assessment of
new compounds.
THE ROLE OF PHARMACOGENOMICS
Pharmacogenomics refers to the variability of the expression of
individual genes relevant to disease susceptibility as well as drug
response at cellular, tissue, individual, or population level. Phar-
macogenetics refers more specifically to the study of individual
variations in DNA sequence related to drug response. The growing
interest in this field is due to the fact that risk/benefit evaluations of
drugs are not fully appreciated if one does not fully consider indi-
vidual variations that may significantly affect pharmacokinetics
and pharmacodynamics.
POLYMORPHISMS AS MARKERS OF DISEASE
As an example, patients with IBS had significantly reduced fre-
quencies of the high producer genotype for interleukin 10 than
controls (21 vs. 32%; p = 0.003): this suggests a genetic predispo-
sition in at least some patients with IBS to produce lower amounts
of the anti-inflammatory cytokine interleukin 10 (Gonsalkorale
et al., 2003) and lends support to the hypothesis that there may
be an inflammatory or genetic component in some cases of IBS
(Bashashati et al., 2012).
POLYMORPHISMS AFFECTING DRUG RESPONSE
Genetic variations can affect drug response in at least three dif-
ferent ways (Camilleri and Katzka, 2012): (a) changes in drug
metabolism, e.g., through functional CYP450 2D6 genes, which
determine the pharmacokinetics and plasma levels of many
commonly used agents such as antidepressants; (b) changes in
drug transporters, which may affect the response to medica-
tions: for instance, polymorphisms in the promoter for synthesis
of serotonin transporter (SERT-P) influence response to sero-
tonergic medications in depressed individuals. SERT polymor-
phisms were associated with a greater colonic transit response
in those with long homozygous than those with heterozygous
polymorphisms in D-IBS (Camilleri et al., 2002); (c) genetic
polymorphism in drug targets. Several examples are provided by
recent studies (Camilleri and Katzka, 2012; Vazquez-Roque et al.,
2012).
In summary, pharmacogenetics is a rapidly growing field which
may provide important pieces of information to fully understand
the variability of drug action in patients and cannot be ignored in
drug development programs, although its exploitation probably
still needs some time.
CLASSES OF DRUGS USED OR UNDER DEVELOPMENT IN IBS
A detailed discussion of all the classes of drugs proposed as poten-
tial therapeutic agents in IBS is beyond the scope of this review.
The main pharmacological approaches to IBS are summarized in
Table 2, which does not include agents traditionally used in IBS,
such as laxatives and antidiarrheal agents, respectively for con-
stipation and diarrhea, and probiotics. The gut microbiome as a
therapeutic target is covered elsewhere (Floch et al., 2011; Simren
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Table 2 | Main pharmacological approaches in IBS.
Drug class Examples Pharmacodynamics
5-HT4 receptor agonists Prucalopride Enteric neurons, smooth muscle cells
Naronapride Increased motility/bowel frequency
Velusetrag
TD-8954
5-HT3-receptor antagonists Ramosetron Inhibition of secretion, motility, nociception
TPH1 blocker LX-1031 Inhibits 5-HT synthesis by blocking tryptophane hydroxylase 1
Cl-C2 channel activator Lubiprostone Increased intestinal water and electrolyte secretion
Accelerates transit
Guanylate cyclase-C agonist Linaclotide Increased intestinal water and electrolyte secretion
Accelerates transit
PAR2 blockers GB88 Inflammation
TRPV1 blockers Capsazepine Inflammation
TRPV4 blockers RN1734
Mast cell stabilizers Ketotifen Inflammation
µ-Opioid receptor agonists Loperamide Enterocyte, enteric neurons, afferent neurons, and inflammation
µ-Opioid receptor antagonists Naloxone Enteric neurons, afferent neurons, and inflammation
Methylnaltrexone alvimopan
κ-Opioid receptor agonists Asimadoline Enteric neurons and afferent neurons
Increase in sensory threshold
β3-Adrenoceptor agonists Solabegron Smooth muscle
α2-Adrenoceptor agonists Clonidine Enteric neurons and enterocytes
NK1 receptor antagonists Ezlopitant Enteric neurons, ICC, smooth muscle, immune cells
NK2 receptor antagonists Nepadutant Reduced smooth muscle contractility
NK3 receptor antagonists Talnetant Role in nociception not confirmed in clinical trials in patients with IBS
CCK1 receptor antagonists Loxiglumide Afferent vagal nerves and enteric neurons
Antibiotics Rifaximin Poorly absorbed with virtually no systemic effects
et al., 2013). The reader is also referred to a recent detailed review of
current and potential pharmacological approaches in IBS (Camil-
leri, 2012). Herbal preparations used in IBS are covered by another
review (Rahimi and Abdollahi, 2012). Brain-gut interactions and
possible sites/mechanisms of pharmacological intervention along
the brain-gut axis are discussed in a recent review in this Journal
(Fichna and Storr, 2012).
Several meta-analyzes of pharmacological treatments for IBS
have been published in recent years and there is ongoing debate
on their interpretation (Lesbros-Pantoflickova et al., 2004; Brandt
et al., 2009; Camilleri and Mayer, 2009).
SEROTONERGIC AGENTS
5-Hydroxytryptamine (5-HT) plays a key role in the control
of gastrointestinal motility, sensitivity, and secretion (De Ponti,
2004). Several 5-HT receptor types are present on both nerves and
smooth muscle and mediate a number of different actions (De
Ponti, 2004). Actions of 5-HT are terminated by a reuptake sys-
tem, which is inhibited by antidepressants (Gershon and Jonakait,
1979). Selective serotonin reuptake inhibitors (SSRIs) alter motility
in the stomach, small bowel, and colon (Gorard et al., 1994), but
no convincing beneficial therapeutic effects have been reported in
IBS. Interestingly, the tryptophane hydroxylase inhibitor LX-1031
was recently reported to have therapeutic potential in IBS (Tack
et al., 2011).
5-HT3 receptor antagonists include alosetron and ramosetron
(Camilleri et al., 2000; Hirata et al., 2007; Lee et al., 2011); alosetron
delays orocecal and colonic transit times, and reduce colonic com-
pliance but not sensitivity to isobaric distension (Gore et al., 1990;
Talley et al., 1990; Scolapio et al., 1995). Shortly after its intro-
duction, alosetron was withdrawn due to suspected side-effects of
colonic ischemia (Moynihan, 2002).
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5-HT4 receptor agonists, after withdrawal of tegaserod, now
include prucalopride, naronapride, velusetrag (Camilleri, 2010b),
and TD-8954 (Beattie et al., 2011). These agents are thought to act
on intrinsic neurons to stimulate gastric, small bowel, and colonic
transit in health, in constipation and in IBS with constipation
(Bouras et al., 1999; Poen et al., 1999; Degen et al., 2001). In the
stomach, 5-HT4 receptor agonists enhance (postprandial) prox-
imal gastric volumes in health, but have no effects on sensation
(Tack et al., 2003). Prucalopride was also shown to be effective in
the treatment of constipation (Emmanuel et al., 2002).
LINACLOTIDE
This is an example of guanylate cyclase-C agonist (Busby et al.,
2013), which has been shown to reduce visceral hypersensitivity
in preclinical studies and to improve abdominal pain and consti-
pation symptoms in phase 2 and 3 clinical trials of patients with
IBS and constipation (Johnston et al., 2013).
LUBIPROSTONE
This is an oral bicyclic fatty acid selectively activating type 2
chloride channels in the apical membrane of the intestinal epithe-
lial cells, hence stimulating chloride secretion, along with passive
secretion of sodium and water, inducing peristalsis and laxation,
without stimulating gastrointestinal smooth muscle (Schey and
Rao, 2011). It is indicated in IBS with constipation. Considering
the importance of epithelial barrier function and cell integrity and
the known impact of stressors, the observation that lubiprostone
exhibits the additional distinct property of effective protection or
repair of the epithelial barrier and cell function after stress suggests
potential clinical importance for patients with impaired barrier
function, which might occur in IBS (Cuppoletti et al., 2012).
TACHYKININ RECEPTOR ANTAGONISTS
Three distinct receptors, NK1, NK2, and NK3, mediate the biolog-
ical effects of endogenous tachykinins SP, NKA, and NKB, in the
gastrointestinal tract. Through the locations of NK receptors on
intrinsic nerves, extrinsic nerves, inflammatory cells, and smooth
muscle, inhibition of tachykinin receptors has the potential to
inhibit motility, sensitivity, secretion, and inflammation in the
gastrointestinal tract (Holzer, 2004a; Lecci et al., 2004). NK1 recep-
tor antagonists also have antiemetic properties (Holzer, 2004a).
Several tachykinin receptor antagonists have been developed so
far, but the results, in general, have been disappointing. Recently,
chronic treatment with AV608 (NK1 receptor antagonist) in IBS
has been reported to be associated with improved mood and pain
ratings and activity of emotional arousal related brain regions
(Tillisch et al., 2012).
ADRENOCEPTOR AGONIST
The α2-adrenoceptor agonist clonidine was shown to reduce
colonic tone and pain sensation in response to distension
(Bharucha et al., 1997; Malcolm et al., 2000; Viramontes et al.,
2001b). A preliminary study of clonidine in IBS with diarrhea
suggested therapeutic potential for clonidine, but clinical applica-
tion is hampered by dose-limiting side-effects like somnolence or
hypotension. Among β3-adrenoceptor agonists, solabegron is an
example (Grudell et al., 2008).
OPIOID RECEPTOR LIGANDS
Three types of opioid receptors, µ-, δ-, and κ-receptors, located in
the ENS as well as on nociceptive pathways, have effects on human
gastrointestinal function. Opioid receptor activation reduces vis-
ceral pain through peripheral (spinal afferents) and central mech-
anisms, and inhibits motility through decreased acetylcholine
release. κ-Opioid receptor agonists have been proposed as a phar-
macological approach to the treatment of altered visceral sen-
sitivity. Acute studies with fedotozine and asimadoline showed
decreased sensitivity to gastric or colonic distension (Coffin et al.,
1996; Delvaux et al., 1999, 2002; Delgado-Aros et al., 2003). How-
ever, therapeutic studies in IBS and FD with fedotozine have
been disappointing (Dapoigny et al., 1995; Read et al., 1997). The
µ-opioid receptor agonist loperamide, used in the treatment of
diarrhea, inhibits secretion, reduces colonic transit, and increases
resting anal sphincter tone (Corazziari, 1999). Peripherally act-
ing µ-opioid receptor antagonists (e.g., N-methylnaltrexone and
alvimopan) normalize bowel function in opiate-treated patients
without compromising central opioid analgesia (Holzer, 2004b).
Racecadotril, a neutral endopeptidase (NEP) inhibitor, increases
the exposure to NEP substrates including enkephalins: it was found
consistently effective in animal models and patients with vari-
ous forms of acute diarrhea by inhibiting secretion from the gut
without changing gastrointestinal transit time or motility (Eber-
lin et al., 2012). In direct comparative studies with loperamide,
racecadotril was at least as effective, but exhibited fewer adverse
events in most studies, particularly less rebound constipation
(Eberlin et al., 2012). However, its potential in IBS remains to
be established.
MISCELLANEOUS AGENTS
CCK has a large number of effects on gastrointestinal contractility
and secretion (Walsh, 1994). CCK1 receptor antagonists like lox-
iglumide and dexloxiglumide enhance gastric emptying in health
and in IBS with constipation, though effects on colonic motil-
ity are unclear (De Ponti and Malagelada, 1998; Scarpignato and
Pelosini, 1999) and clinical usefulness has not been established.
The transient receptor potential ion channel of the vanilloid
type 1 (TRPV1), expressed by primary afferent neurons, is viewed
as a trigger for chemonociception and may be upregulated in some
functional gut disorders (Chan et al., 2003). TRPV1 and TRPV4
blockade are areas of current investigation (Holzer, 2011; Fichna
et al., 2012).
Muscarinic receptor antagonists and smooth muscle relaxants are
used in some countries for the treatment of IBS. Meta-analysis
suggests they are superior to placebo in IBS-related pain (Poynard
et al., 2001), though the quality of trials is often questionable.
Cannabinoid CB1 receptors are expressed on nociceptive affer-
ents and ENS neurons while CB2 receptors are expressed on
immune cells (Schicho and Storr, 2011). Activation of CB1 recep-
tors slows gastrointestinal transit in animals through inhibi-
tion of acetylcholine release. The non-specific agonist delta-9-
tetrahydrocannabinol has strong antiemetic properties and delays
gastric emptying in humans (Frytak et al., 1979; McCallum et al.,
1999). The observation that, in an animal model of intestinal
inflammation, CB1 and CB2 receptor subtypes are upregulated
opens a new perspective on the possible use of CB1 or CB2 receptor
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agonists in postinfectious IBS with diarrhea (Kimball et al., 2010).
Indeed, dronabinol, a non-selective CB agonist, reduces fasting
colonic motility in patients with IBS with diarrhea or alternating
(Wong et al., 2011).
Finally, α2δ ligands such as gabapentin and pregabalin (Gale
and Houghton, 2011) have undergone a number of preclinical and
clinical tests for their potential in disorders with visceral hyper-
sensitivity. In fact, voltage-sensitive Ca2+ channels are involved
in neural function and have an α2δ binding site to which the
aforementioned ligands bind potently, reducing Ca2+ influx at the
nerve terminals. Pregabalin was effective in several animal models
of visceral pain (Gale and Houghton, 2011).
CONCLUSION
From the above overview, it is clear that research in the treat-
ment of IBS is still very active. Although in the past decade some
innovative pharmacological agents have not fulfilled their promise
because of unexpected side-effects, it is likely that new pathophys-
iological concepts as well as the publication of new regulatory
documents by the FDA and the EMA will be of great help for drug
developers.
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